We aimed to construct a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA + -M2BP) level in patients with chronic hepatitis C (CHC) and to validate its accuracy in an independent cohort.
INTRODUCTION

C HRONIC HEPATITIS C infection is a leading etiology of HCC.
1 Despite significant efficacy of direct-acting antiviral agents, the morbidity and incidence of CHCrelated complications, such as development of HCC, is likely to persist in the near future. 2, 3 The risk for development of HCC in patients with CHC is associated with liver fibrosis stage. In cirrhotic subjects, the annual incidence of HCC in Japan is extremely high (approximately 7% per year). 4, 5 Although the introduction of highly effective direct-acting antiviral agents for CHC patients is expected to reduce the incidence of CHC-related HCC, the achievement of a sustained virological response does not mean that it eliminates the risk of HCC, especially when the subjects have already developed advanced liver fibrosis. 2, 3, 6 Thus, identifying patients with advanced liver fibrosis is clinically essential. As liver biopsy is an invasive procedure, other non-invasive methods for evaluating liver fibrosis are required.
The WFA + -M2BP was recently established in Japan as a glycobiomarker linked to liver fibrosis in patients with CHC with a unique fibrosis-related glycoalteration and rapid bedside method. [7] [8] [9] Recent studies also showed that WFA + -M2BP can be helpful for clinical outcome in HCC patients treated with surgical resection or in CHC patients treated with antiviral therapy. 6, [10] [11] [12] In addition, in our previous studies, we showed that WFA + -M2BP can be helpful for predicting the degree of liver fibrosis in patients with autoimmune hepatitis and primary biliary cirrhosis. 13, 14 Several predictive models for assessing liver fibrosis such as APRI, the FIB-4 index, AST to ALT ratio, and Forns index have been previously proposed and externally validated. [15] [16] [17] [18] [19] [20] However, to the best of our knowledge, there have been no reports of a predictive model containing WFA + -M2BP level for assessing the degree of liver fibrosis. Such a predictive model could be a point of focus in the future. The goal of the current study is to construct a predictive model containing WFA + -M2BP level for advanced fibrosis in patients with CHC and to validate its accuracy in an independent cohort.
METHODS
Patients
B
ETWEEN JANUARY 2006 and July 2015, a total of 386 individuals with HCV-related liver disease with available stored sera were admitted to the Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine (Hyogo, Japan) and were included in this analysis. Subjects with HCV-related liver disease are defined as those with HCV antibody positive and hepatitis B surface antigen negative. All subjects underwent liver biopsy. In the current analysis, we included the following variables in the analysis: age, gender, HCV genotype, HCV viral load, serum albumin, total bilirubin, AST, ALT, ALP, GGT, total cholesterol, triglyceride, PT, platelet count, fasting blood glucose, hyaluronic acid, and serum WFA + -M2BP level. For the purpose of this study, we formed a training set in whom liver biopsy was carried out from January 2006 to December 2010 (n = 210). In the training set, we investigated variables linked to the presence of advanced fibrosis using univariate and multivariate analyses and constructed a formula for predicting the presence of advanced fibrosis. Second, we evaluated the reproducibility of that model in the subsequent validation set, which included patients at a different time period. Patients in the training set were investigated retrospectively and the constructed algorithm was also tested in a retrospective manner for the independent validation set.
The ethics committee of our hospital approved the current study protocol and this study protocol complied with all of the provisions of the Declaration of Helsinki.
Histological findings
In our hospital, percutaneous liver biopsy was routinely carried out under ultrasonographic guidance and using 16-gauge biopsy needle. Liver biopsy specimens were obtained using standard methods, and well experienced pathologists in our hospital evaluated the samples. All biopsy specimens had a minimum of 15 mm length of liver tissue with five or more portal tracts. Fibrosis stages were staged on a degree of F0-F4 (F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with rare septa; F3, numerous septa without cirrhosis; and F4, liver cirrhosis). Liver inflammation activity stages were staged as: A3, severe degree of liver inflammation; A2, moderate degree of liver inflammation; A1, mild degree of liver inflammation; and A0, no liver inflammation. No procedure-related death, related to liver biopsy, was observed. In this study, advanced fibrosis was defined as F3 or more.
Measurement of WFA + -M2BP
Stored sera was used for WFA + -M2BP testing. Quantification of WFA + -M2BP was measured based on a lectinantibody sandwich immunoassay using the fully automatic immunoanalyzer, HISCL-2000i (Sysmex, Hyogo, Japan). 21 The measured values of WFA + -M2BP conjugated to WFA were indexed with obtained values using the following equation:
is the WFA + -M2BP count of the serum sample, NC is the negative control, and PC is the positive control. The PC was supplied as a calibration solution preliminarily standardized to yield a COI value of 1.0.
21,22
Calculation of ARPI, FIB-4 index, and Forns index
The APRI score was calculated using Wai's formula:
The FIB-4 index was calculated using Sterling's formula:
Forns index was calculated using Forns's formula as: 
Validation set
The validation dataset (subjects in whom liver biopsy was carried out between January 2011 and July 2015 in our hospital [n = 176]) was used to assess the performance of the novel predictive score.
Statistical analysis
A predictive model to identify advanced fibrosis was built from subjects in the training set and validated in the separate, independent validation set. First, as described above, univariate analysis was carried out to detect candidate variables among various clinical factors to generate a new formula. Variables with P < 0.01 in univariate analysis were included in the multivariate logistic regression analysis. Factors with P < 0.10 in the multivariate analysis were finally selected as components of the new formula. Based on these multivariate predictors, we derived a multiple fractional equation for prediction of advanced fibrosis in the training set. A predictive model was constructed by modeling the values of variables with P < 0.10 in our multivariate analysis and their coefficients of regression. 18 The ROC analysis was carried out for calculating the AUROC and for selecting the optimal cut-off value that maximized the sum of sensitivity and specificity for the presence of advanced fibrosis in the training set. Thereafter, in the subsequent validation set, we tested the diagnostic value of the formula that was derived from the training set.
In continuous variables, the statistical analysis between two groups was carried out using Student's t-test or the Mann-Whitney U-test, as appropriate. Categorical variables were compared using Fisher's exact tests or Pearson's χ 2 -test, as appropriate. The corresponding AUROC, sensitivity, specificity, PPV, NPV, and diagnostic accuracy were also represented along with the ROC curve analysis. Data are expressed as means ± standard deviation. Values of P < 0.05 were considered to be statistically significant. Statistical analysis was undertaken with the JMP 11 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Baseline characteristics
T HE BASELINE CHARACTERISTICS in the training set (n = 210) and the validation set (n = 176) in the present study are shown in Table 1 . In the training set, Univariate and multivariate analyses of factors associated with presence of advanced liver fibrosis Univariate analysis identified the following factors as significantly associated with the presence of advanced fibrosis for the training set: age (P < 0.001); AST (P < 0.001); ALT (P = 0.029); ALP (P < 0.001); GGT (P = 0.012); total bilirubin (P = 0.013); albumin (P < 0.001); PT (P < 0.001); platelet count (P < 0.001); total cholesterol (P < 0.001); fasting blood glucose (P = 0.021); hyaluronic acid (P < 0.001); and WFA + -M2BP (P < 0.001) ( Table 2 ). The hazard ratios and 95% confidence intervals calculated using multivariate analysis for the nine factors with P < 0.01 in univariate analysis are detailed in Table 3 . Prothrombin time (P = 0.018) and WFA + -M2BP (P = 0.029) were found to be significant prognostic factors linked to the presence of advanced fibrosis, whereas platelet count (P = 0.098) and hyaluronic acid (P = 0.078) showed borderline statistical significance for the presence of advanced fibrosis. 
Diagnostic performance for advanced fibrosis
The factors WFA + -M2BP, PT, platelet count, and hyaluronic acid were incorporated into the final model to develop the prediction formula for advanced fibrosis in the training set. The system was named the MPPH score by using the initial character of M2BP (M), PT (P), platelet count (P) and hyaluronic acid (H).The equation for the model is:
The AUROCs, optimal cut-off point, sensitivity, specificity, PPV, NPV, and diagnostic accuracy for WFA + -M2BP, AST to ALT ratio, APRI, FIB-4 index, Forns index, PT, platelet count, hyaluronic acid, and our proposed MPPH score in the training set are presented in Table 4 and Figure 1 . Among eight variables, MPPH score yielded the highest AUROC with a level of 0.87. Optimal cut-off points in the training set in each variable were applied to the validation set, and the AUROCs, sensitivity, specificity, PPV, NPV, and diagnostic accuracy for WFA + -M2BP, AST to ALT ratio, APRI, FIB-4 index, Forns index, PT, platelet count, hyaluronic acid, and MPPH score in the validation set are shown in Table 4 Figure 3 . In WFA + -M2BP, the differences between two liver fibrosis stages (F0 or F1 vs. F2; F2 vs. F3; F3 vs. F4; F0 or F1 vs. F3; F2 vs. F4; and F1 vs. F4) reached significance, except for the difference between F0 or F1 vs. F2 (P = 0.083). In the MPPH score, all differences between two liver fibrosis stages reached significance (Fig. 3) .
Proportion of patients with advanced fibrosis based on MPPH score for all cases
We calculated the proportion of advanced fibrosis based on MPPH score. For convenience, we classified all cases into three groups: patients with MPPH score < À1 (group A, n = 117); patients with À1 < MPPH score < 1 (group B, n = 169); and patients with MPPH score > 1 (group C, n = 100). The proportions of advanced fibrosis in the three groups were 92.3% (108/117) in group A, 50.9% (86/ 169) in group B, and 18.0% (18/100) in group C. The proportions of advanced fibrosis were significantly stratified between each two groups (all P-values <0.001) (Fig. 4) .
Proportion of advanced fibrosis based on MPPH score in patients aged ≥65 years and those aged <65 years
We undertook a subgroup analysis in patients aged ≥65 years (n = 154). They included 66 patients in group A (MPPH score < À1), 72 patients in group B (À1 < MPPH The proportions of advanced fibrosis in the three groups were 92.4% (61/66) in group A, 58.3% (42/72) in group B, and 18.8% (3/16) in group C. The proportions of advanced fibrosis were well stratified with statistical significance in each two-group comparison (all P-values <0.001) (Fig. 5a ) Similarly, we carried out subgroup analysis in patients aged <65 years (n = 232). They included 51 patients in group A (MPPH score < À1), 97 patients in group B (À1 < MPPH score < 1), and 84 patients in group C (MPPH score > 1). The proportions of advanced fibrosis in the three groups were 92.2% (47/51) in group A, 45.4% (44/97) in group B, and 17.9% (15/84) in group C. The proportions of advanced fibrosis were well stratified with statistical significance in each two-group comparison (all P-values <0.001) (Fig. 5b) .
Proportion of advanced fibrosis based on MPPH score in patients aged ≥70 years and those aged <70 years Similarly, we undertook subgroup analysis in patients aged ≥70 years (n = 82). They included 44 patients in group A (MPPH score < À1), 35 patients in group B (À1 < MPPH score < 1), and 3 patients in group C (MPPH score > 1). The proportions of advanced fibrosis in the three groups were 95.5% (42/44) in group A, 54.3% (19/ 35) in group B, and 33.3% (1/3) in group C. The proportions of advanced fibrosis were well stratified with statistical significance in each two-group comparison except for the comparison of groups B and C (P = 0.585) (Fig. 6a) In patients <70 years old (n = 304), they included 73 patients in group A (MPPH score < À1), 134 patients in group B (À1 < MPPH score < 1), and 97 patients in group C (MPPH score > 1). The proportions of advanced fibrosis in the three groups were 90.4% (66/73) in group A, 50.0% (67/134) in group B, and 17.5% (17/97) in group C. The proportions of advanced fibrosis were well stratified with statistical significance in each two-group comparison (all P-values <0.001) (Fig. 6b) . score for all cases (n = 386). Group A, patients with MPPH score < À1; Group B, patients with À1 < MPPH score < 1; Group C, patients with MPPH score > 1.
DISCUSSION
L IVER BIOPSY IS an invasive procedure, so a simple predictive model for advanced liver fibrosis is required in daily clinical practice. To the best of our knowledge, our proposed MPPH score is the first scoring system for assessment of advanced liver fibrosis in patients with CHC. As WFA + -M2BP has recently attracted much attention as a novel liver fibrosis marker among Japanese hepatologists, our current study may be of clinical importance.
In our data, among eight variables, MPPH score yielded the highest AUROC with a level of 0.87 in the training set Figure 5 Prevalence of advanced fibrosis based on Wisteria floribunda agglutinin-positive Mac-2-binding protein, prothrombin time, platelet count, and hyaluronic acid (MPPH) score in patients aged ≥65 years (n = 154) (a) and in patients aged <65 years (n = 232) (b). Group A, patients with MPPH score < À1; Group B, patients with À1 < MPPH score < 1; Group C, patients with MPPH score > 1. Figure 6 Prevalence of advanced fibrosis based on Wisteria floribunda agglutinin-positive Mac-2-binding protein, prothrombin time, platelet count, and hyaluronic acid (MPPH) score in patients aged ≥70 years (n = 82) (a) and in patients aged <70 years (n = 304) (b). Group A, patients with MPPH score < À1; Group B, patients with À1 < MPPH score < 1; Group C, patients with MPPH score > 1.
Predictive model, liver fibrosis and WFA + and in the validation set, MPPH score also yielded the highest AUROC (0.83) among eight variables. In addition, in the training (81.4%) and validation sets (74.4%), MPPH score had the highest diagnostic accuracy among eight variables. Overall, combinations of tests still appear to have greater accuracy than single markers for predicting advanced fibrosis in patients with CHC. In a comparison of WFA + -M2BP and MPPH score according to liver fibrosis stage, the differences between liver fibrosis stages reached significance in MPPH score but not in WFA + -M2BP. Furthermore, in all subgroup analyses, prevalence of advanced liver fibrosis was significantly stratified according to MPPH score in each two-group comparison except for the comparison of groups B and C in patients aged ≥70 years. These results show that our proposed MPPH scoring system can be a useful scoring system for predicting advanced fibrosis in patients with CHC. One of the major strengths of this study is that our hypothesis was tested in the independent cohort, although the independent validation set was recruited in a retrospective manner. Another major strength of our current analysis is its large sample size.
In 2004, Rosenberg et al. reported that the combination of multiple serum markers, including hyaluronic acid, Nterminal propeptide of type III collagen, and tissue inhibitor of matrix metalloproteinase 1, is useful for assessing the degree of liver fibrosis. 23 A comparison of their results with and ours showed that AUROCs for advanced fibrosis in our data (0.87 or 0.83) were higher than in Rosenberg et al.'s results (0.804). 23 As in our study N-terminal propeptide of type III collagen and tissue inhibitor of matrix metalloproteinase 1 were not tested, direct comparison between these studies is difficult. However, current results indicate that our proposed scoring system is a promising scoring system.
FibroScan is a rapid and user-friendly device for assessing liver fibrosis that can easily be used at the bedside or in the outpatient clinic with immediate results and good reproducibility. 24, 25 A previous meta-analysis confirmed that FibroScan is adequate for the diagnosis of advanced fibrosis or liver cirrhosis compared with mild fibrosis.
26
Previously published data showed that the AUROC for advanced fibrosis diagnosed with FibroScan was reported to range from 0.72 to 0.97; in our data, AUROCs for the MPPH score for advanced fibrosis were 0.87 in the training set and 0.83 in the validation set. 26 Thus, the diagnostic ability of the MPPH score may be identical to that of FibroScan for diagnosis of advanced fibrosis. A recent meta-analysis also reported that ARFI elastography, which is a novel procedure enabling assessment of the degree of liver fibrosis during a conventional ultrasonographic examination, was a good method for assessing liver fibrosis, and showed a higher rate of reliable measurements and similar predictive value to FibroScan for significant fibrosis and cirrhosis. 27 Thus, in a sense, our proposed MPPH score could be an alternative assessment method to FibroScan or ARFI. However, further examinations will be needed to confirm these results.
In our subgroup analysis in patients aged 65 years or more, 92.4% of patients with MPPH <À1 had advanced fibrosis, whereas in patients younger 65 years, 92.2% of patients with MPPH <À1 had advanced fibrosis. In addition, in patients aged 70 years or more, 95.5% of patients with MPPH <À1 had advanced fibrosis, while in patients younger 70 years, 90.4% of patients with MPPH <À1 had advanced fibrosis. This means that lower MPPH score can be helpful for predicting advanced fibrosis irrespective of age. To the contrary, in patients with MPPH >2 (n = 13) in the overall cohort, only one patient (7.7%) had advanced fibrosis and in patients with MPPH >1.5 (n = 66) in overall cohort, 7 patients (10.6%) had advanced fibrosis. In such patients, liver biopsy will not be needed for predicting advanced liver fibrosis. For reducing the rate of liver biopsyrelated serious complications, this may be an important recommendation based on our current results.
Nine patients with MPPH score < À1 were judged as having no advanced fibrosis in the present study. In terms of histological findings for these patients, F1 was found in two patients and F2 was found in the remaining patients. All these patients had platelet counts less than 12.0 × 10 4 /mm 3 , which indicates having clinically advanced fibrosis. These discrepancies may be attributed to the interpretation of liver biopsy samples.
Aging is an impending problem in patients with CHC. 28 Indeed, FIB-4 index and Forns index involve age, whereas in our study, age was not a significant predictor (P = 0.20) linked to advanced fibrosis in our multivariate analysis and thus was not included in the final model. Aging accelerates liver fibrosis progression. 28, 29 One possible reason for these results is that aging-related variables diminished the effect of age in the multivariate analysis.
We acknowledge several limitations to this study. First, as our study is a retrospective longitudinal study, our data should be interpreted with caution. Second, as we used only internal validation, our findings require prospective external validation. Third, as the samples were all selected from the Japanese population, further investigation is required to determine whether our results could be extrapolated to populations with different ethnic backgrounds; thus, the MPPH score deserves to be further validated in non-Japanese populations. Finally, liver biopsy has the limitation of being prone to sampling errors for evaluating the degree of liver fibrosis, leading to bias. However, our current results showed that our proposed prediction model performed well as a screening tool for identifying CHC patients with advanced fibrosis. In conclusion, our proposed MPPH scoring system could be a useful scoring system for predicting advanced liver fibrosis in CHC patients.
ACKNOWLEDGMENTS
T HE AUTHORS WOULD like to thank Nozomi Kanazawa, Yoko Matsushita, and Sayaka Fujii for data collection.
